US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology Market Research Reports & Industry Analysis

RSS Feeds

CNS/Neurology Industry Research & Market Reports

3  4  5  6    8    10  11  12  
Mild Cognitive Impairment - Pipeline Review, H1 2014
4/28/2014 | published by: Global Markets Direct
... information on the therapeutic development for Mild Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
USD 2,000
Partial Seizure - Pipeline Review, H1 2014
4/28/2014 | published by: Global Markets Direct
... therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Sumavel DosePro (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of ...  |  read more...
USD 3,495
Antidepressants (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
Calcium Channel Antagonists (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes ...  |  read more...
USD 3,495
Botox (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
Zecuity (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
Levadex (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
RHB-103 (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
AVP-825 (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
SUD-001 (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023
5/1/2014 | published by: GlobalData
... cells in the brain and the spinal cord. ALS severely impacts physical functioning and initially presents with muscle twitching, weakness in an arm or leg, or with slurring of speech. Eventually, people with ALS lose ...  |  read more...
USD 3,995
Memory Impairment - Pipeline Review, H1 2014
4/30/2014 | published by: Global Markets Direct
... therapeutic development for Memory Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Progressive Supranuclear Palsy - Pipeline Review, H1 2014
5/15/2014 | published by: Global Markets Direct
... information on the therapeutic development for Progressive Supranuclear Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
USD 2,000
2014 U.S. Patient care - Nervous system & sense organ disorders sold through Offices of physicians-Product & Services Report
4/15/2014 | published by: Barnes Reports
... of physicians-Product & Services Report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2014 current and 2015 forecast estimates on the sales of Patient care - ...  |  read more...
USD 199
2014 U.S. Patient care - Nervous system & sense organ disorders sold through Medical & surgical hospitals-Product & Services Report
4/15/2014 | published by: Barnes Reports
... Medical & surgical hospitals-Product & Services Report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2014 current and 2015 forecast estimates on the sales of Patient ...  |  read more...
USD 199
Traumatic Brain Injury - Pipeline Review, H1 2014
4/28/2014 | published by: Global Markets Direct
... information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
USD 2,000
Brain Ischemia - Pipeline Review, H1 2014
5/21/2014 | published by: Global Markets Direct
... therapeutic development for Brain Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Asperger Syndrome Global Clinical Trials Review, H1, 2014
5/21/2014 | published by: GlobalData
... information and data relating to the clinical trials on Asperger Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ...  |  read more...
USD 2,500
Agoraphobia Global Clinical Trials Review, H1, 2014
5/26/2014 | published by: GlobalData
... relating to the clinical trials on Agoraphobia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage ...  |  read more...
USD 2,500
Market Highlights: Italy Depression – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, depression drugs market share, depression drugs sales estimates, depression drugs sales forecast, and depression late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Update: Narcolepsy Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing ...  |  read more...
USD 590
Market Highlights: Spain Depression – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, depression drugs market share, depression drugs sales estimates, depression drugs sales forecast, and depression late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Germany Depression – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, depression drugs market share, depression drugs sales estimates, depression drugs sales forecast, and depression late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Italy Glioblastoma – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, glioblastoma drugs market share, glioblastoma drugs sales estimates, glioblastoma drugs sales forecast, and glioblastoma late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
3  4  5  6    8    10  11  12